Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

NervGen Pharma Corp V.NGEN

Alternate Symbol(s):  NGENF

NervGen Pharma Corp. is a clinical-stage biotech company. The Company is engaged in discovery, development and commercialization of pharmaceutical products for the treatment of nervous system damage due to injury or disease. The Company is advancing its lead compound, NVG-291, for the treatment of spinal cord injury (SCI), Alzheimer’s disease (AD) and multiple sclerosis (MS). Its NVG-291 is a therapeutic peptide, which is a mimetic of the intracellular domain of protein tyrosine phosphatase, a cell surface receptor known to interact with chondroitin sulfate proteoglycans (CSPGs) and to be involved in the regulation of neuroplasticity and central nervous system repair. It has also initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. The Company's wholly owned subsidiaries include NervGen US Inc. and NervGen Australia Pty Ltd.


TSXV:NGEN - Post by User

Post by deepoil0808on Apr 25, 2024 8:38pm
321 Views
Post# 36008456

Sedar filings HINT at inconclusive evidence (more testing)?

Sedar filings HINT at inconclusive evidence (more testing)?I conducted a review of the insider buying from February 15th 2024 to date.  

The date of February 15th is when there were leaks of one patient doing well, followed up later with free clinical trials to placebo group. 

These two hints pointed to a success.

However when I looked at the sedar insider filings I was clearly very disappointed as the corporate body language displayed is one of a lack of greed = lack of confidence = inconclusive results. 

I will give examples.   One insider sold for $ 450,000 worth of shares and only bought back $ 100,000.     Another bought shares just on the exercise of option.  A great majority of others bought shares in quantities that normal retail shareholders would buy (ie:  +/- 10,000 shares,  +/- 20,000 shares, +/- 40,000 shares).    The biggest buys were from top management at +/- 150,000 shares.

I remember when I was in Dendreon company and they were waiting for explosive results, insiders were loading up in the millions of shares and so were institutions despite the rumour going around that results would fail, everyone was buying like crazy.

Here buying is to be desired.   Now they hire a PR firm.   Why?    If results are great they will speak to themselves.   You do not need a PR. 

I think financing was was the key hint as greed would have dictated that you do an offering after the results when stock is $ 30.   If you do it at $2.35 it means that you are not confident and do not want to take the risk.  It also means that you see this as the high. 

My view is that results are INCONCLUSIVE, need more testing as one person getting better is insufficent. 

Remember this is my personal opinion, I could be totally wrong in my analysis.  I have no position in this stock either up or down and, am not paid by anyone.  I am not giving investment advice either.   Just a retail investor with a curiousity peak into NVGN and sharing an opinion.

If I do see something that convinces me that results are positive then I will certainly jump in, but to me it looks like more of a disappointment at this point. 

Good Luck to all of you.


<< Previous
Bullboard Posts
Next >>